Bird & Bird ATMD wins trade mark and passing off action for pharmaceutical giant, Allergan Inc.

Contacts

pin ping oh module
Pin-Ping Oh

Partner
Singapore

As a partner in our Intellectual Property Group in Singapore and part of the Media, Entertainment & Sports team, I focus on contentious IP matters including IP infringement litigation, patent revocation actions and trade mark oppositions, but also advise clients extensively on non-contentious matters including IP commercialisation, patent and trade mark freedom-to-operate issues and brand protection.

Bird & Bird ATMD LLP's Intellectual Property team, including Alban Kang (Partner) and Oh Pin-Ping (Counsel), has secured a win for Allergan, Inc., the maker of well-known products such as BOTOX and LATISSE, in a trade mark infringement and passing off claim before the Singapore High Court.

In its Judgment in Allergan, Inc. and anor. v Ferlandz Nutra Pte Ltd, the court held that the defendant's promotion and sale of its cosmetic product "LASSEZ" touted to promote eyelash growth infringed Allergan's registered trade mark for "LATISSE" in Class 5 for "pharmaceutical product for the treatment of eyelashes", and also amounted to passing-off.

Allergan's trade mark infringement claim by reference to the defendant's use of the identical "LATISSE" mark in a comparative advertisement also succeeded. The court rejected the defendant's defence of "fair use" for comparative advertising under section 28(4) of the Trade Marks Act (Cap. 332) based on its finding that the advertisement was materially misleading.

The case is significant as it is the first local decision on the comparative advertising defence. It also marks the first time that the High Court considered the question of whether end-users should be included as part of the relevant public in the likelihood of confusion analysis for trade mark infringement where the subject mark is used in respect of a pharmaceutical product. The court held that the possibility of confusion amongst end-users should be taken into account in this case as the evidence showed that end-users were significantly involved in selecting the products.

News & Deals

More News & Deals

Deal

Bird & Bird advises RIVE on an additional €270 million bank financing

Jan 21 2025

Read More

Deal

Bird & Bird advised Nexstim on cooperation and investment agreements with Brainlab

Jan 20 2025

Read More

Deal

Bird & Bird advises CDP Venture Capital on Series A investment into Naturbeads

Jan 20 2025

Read More

Deal

Bird & Bird advises Endeit Capital on its Series B investment in Nomupay

Jan 17 2025

Read More

News

Bird & Bird strengthens London IP team with new brand management partner

Jan 13 2025

Read More

News

Bird & Bird and Keep the Archipelago Tidy Association launch pro bono partnership

Jan 13 2025

Read More